EMD Millipore, the Life Science division of Merck KGaA of Darmstadt, Germany, recently introduced the Magna Nuclear RNA-binding Protein Immunoprecipitation (RIP) kits. These kits are specially designed to allow the discovery and analysis of both coding and non-coding chromatin-associated RNAs. Two versions of the kit are available, enabling users to analyze RNA both strongly and weakly associated with chromatin; one version uses cross-linked chromatin while the other uses native chromatin. Native RIP allows recovery of high affinity, more direct interactions while the cross-linked method is designed to capture higher molecular weight complexes and more readily trap weaker interacting RNAs.
Compared with other kits available to researchers, the Magna Nuclear RIP kits deliver much lower background signals, high signal-to-noise ratios and have been demonstrated to work in RNA-seq to enable NGS-based discovery and profiling. The kits offer flexible and scalable input requirements; RNA can be recovered from as few as 5,000 cells (cross-linked) or 100,000 cells (native).
"A significant amount of research is being invested in understanding the complex nature of how various chromatin-associated RNAs impact gene expression and epigenetic regulation," said Christophe Couturier, Senior Vice President and Head of the EMD Millipore Bioscience Business Area. "With the Magna Nuclear RIP kits, researchers now have complete, user-friendly kits to facilitate isolation and identification of regulatory RNAs such as short and long non-coding RNAs, snRNAs and enhancer RNAs."
These new kits add to the family of Magna RIP kits first introduced in 2009, which allowed for analysis of cytoplasmic and nuclear-associated RNA molecules. With the new Magna Nuclear RIP kits, researchers can target those proteins associated with RNA in a chromatin context.
About EMD Millipore
EMD Millipore is the Life Science division of Merck KGaA of Germany and offers a broad range of innovative, performance products, services and business relationships that enable our customers' success in research, development and production of biotech and pharmaceutical drug therapies. Through dedicated collaboration on new scientific and engineering insights, and as one of the top three R&D investors in the Life Science Tools industry, EMD Millipore serves as a strategic partner to customers and helps advance the promise of life science.
Headquartered in Billerica, Massachusetts, the division has around 10,000 employees, operations in 66 countries and 2013 revenues of €2.6B. EMD Millipore is known as Merck Millipore outside of the U.S. and Canada. For more information, visit www.emdmillipore.com/epigenetics.
SOURCE: EMD Millipore